Related Experiment Video
Updated: Jan 10, 2026

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
Long-Term Efficacy of Guideline-Followed Treatment in Patients with Livedoid Vasculopathy: A Single-Center Study
Carina Hillgruber1, Carolin Mitschang1, Maria Eveslage2
1Department of Dermatology, University of Muenster, Muenster, Germany.
Insights
Long-term anticoagulation therapy, including rivaroxaban, effectively manages livedoid vasculopathy symptoms like pain and disease activity. This guideline-adherent treatment significantly improves patients
Area of Science:
- Dermatology
- Vascular Medicine
- Pharmacology
Background:
- Livedoid vasculopathy is a painful skin condition causing leg ulcerations and scarring (atrophie blanche) due to microcirculation thrombosis.
- Current treatment options are limited, with no approved therapies, necessitating off-label use.
- The German S1 guideline recommends anticoagulation as first-line therapy.
Purpose of the Study:
- To evaluate the long-term efficacy of guideline-adherent anticoagulation treatment for livedoid vasculopathy.
- To assess the impact of treatment on pain, disease activity, quality of life, and daily life.
Main Methods:
- A single-center, follow-up study of 26 patients with livedoid vasculopathy.
- Patients received treatment according to the German S1 guideline (anticoagulants like rivaroxaban).
- Data collected via questionnaire on demographics, treatment, disease course, quality of life (DLQI), and daily impact.
Main Results:
- Prolonged guideline-followed treatment effectively managed pain and disease activity in livedoid vasculopathy patients.
- Patients reported high therapy satisfaction and sustained improvements in quality of life.
- The study analyzed treatment efficacy over periods ranging from 3 to over 24 months.
Conclusions:
- Guideline-adherent anticoagulation therapy, including rivaroxaban, is an effective long-term treatment for livedoid vasculopathy.
- This approach leads to significant improvements in patient outcomes and quality of life.
Abstract:
Objective: Livedoid vasculopathy is a skin disease characterized by recurrent painful ulcerations of the lower leg leading to scar formation (atrophie blanche). Ulceration results from thrombosis of the cutaneous microcirculation and is often preceded by irregular broken circles of skin discoloration (livedo racemosa) in the lower extremities. Intense local ischemic pain, ulcerations, and irreversible scarring have a severe impact on patients' quality of life. There are currently no approved treatments for livedoid vasculopathy, making off-label therapy the only option. The German S1 guideline for treatment of livedoid vasculopathy recommends anticoagulation with low-molecular-weight heparins, rivaroxaban, and other direct oral anticoagulants as first-line therapy. Approach: We present a single-center follow-up study of 26 patients with livedoid vasculopathy (following STROBE). Patients treated according to the German S1 guideline consented to be monitored with a cross-sectional study questionnaire providing data on demographics, treatment protocol, disease course (pain, disease activity, and relapses), quality of life (Dermatology Life Quality Index score), and daily life impact. Results: Prolonged guideline-followed treatment of livedoid vasculopathy leads to effective management of pain and disease activity. Patients report therapy satisfaction and profit by sustained benefits in quality of life. Innovation: In this study, we analyzed the long-term efficacy of guideline-followed treatment in patients with livedoid vasculopathy over a period of up at least 3 months to more than 24 months. Conclusion: Guideline-followed treatment with anticoagulants like rivaroxaban is an effective long-term therapy option for patients with livedoid vasculopathy.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Rheumatic Heart Disease III: Medical Management
Endocarditis III: Medical Management
Peripheral Artery Disease III: Interprofessional Care
